<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04730050</url>
  </required_header>
  <id_info>
    <org_study_id>TT01025US01</org_study_id>
    <nct_id>NCT04730050</nct_id>
  </id_info>
  <brief_title>A Phase I Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetic Characteristics of TT-01025-CL in Healthy Subjects</brief_title>
  <official_title>A Phase I, First-In-Human, Randomized, Double Blind, Placebo Controlled, Single Ascending-Dose and Multi Ascending Dose Study of TT-01025-CL in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Chem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Chem</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety, tolerability and pharmacokinetic characteristics of TT-01025 in healthy&#xD;
      male subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 17, 2021</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 7 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>up to 7 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life</measure>
    <time_frame>up to 7 days post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Drug: TT-01025-CL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TT-01025-CL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of TT-01025-CL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TT-01025-CL</intervention_name>
    <description>Oral tablet</description>
    <arm_group_label>Drug: Placebo</arm_group_label>
    <arm_group_label>Drug: TT-01025-CL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent must be obtained before any assessment is performed.&#xD;
&#xD;
          -  Age ≥ 18 years and ≤ 55 years, male or female.&#xD;
&#xD;
          -  Body mass index (BMI) between 18 and 30 kg/m2, inclusive, and weighs at least 50 kg.&#xD;
&#xD;
          -  No clinically significant findings in medical examination, including physical&#xD;
             examination, 12-lead electrocardiogram (ECG) and clinical laboratory tests.&#xD;
&#xD;
          -  Male participant and his female spouse/partner who is of childbearing potential agree&#xD;
             to use highly effective contraception* consisting of two forms of birth control (at&#xD;
             least one of which must be a barrier method) from signing of informed consent&#xD;
             throughout the study period and for 90 days after final study drug administration.&#xD;
&#xD;
          -  A female subject of childbearing potential who is sexually active agrees to use highly&#xD;
             effective contraception* consisting of two forms of birth control (at least one of&#xD;
             which must be a barrier method) from signing of informed consent throughout the&#xD;
             duration of the study period and for 90 days after last study drug administration. If&#xD;
             the next menstrual period is delayed, a pregnancy test will be required for exclusion&#xD;
             of pregnancy.&#xD;
&#xD;
               -  Highly effective contraception is defined as:&#xD;
&#xD;
                    -  Established use of oral, injected, or implanted hormonal methods of&#xD;
                       contraception&#xD;
&#xD;
                    -  Placement of an intrauterine device or intrauterine system&#xD;
&#xD;
                    -  Barrier methods of contraception: condom with spermicidal foam, gel, film,&#xD;
                       cream, suppository or occlusive cap (diaphragm or cervical/vault caps) with&#xD;
                       spermicidal foam, gel, film, cream, or suppository&#xD;
&#xD;
          -  Able to understand and sign informed consent and to comply with the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any history of clinically serious disease.&#xD;
&#xD;
          -  Any active or unstable clinically significant medical condition as judged by the&#xD;
             investigator.&#xD;
&#xD;
          -  Subject has abnormal Screening findings or Day -2 laboratory value that suggest a&#xD;
             clinically significant underlying disease.&#xD;
&#xD;
          -  Hypersensitivity or allergy to any of the study drugs, drugs of similar chemical&#xD;
             classes.&#xD;
&#xD;
          -  Received any investigational drug within 30 days or 5x T1/2 whichever is longer before&#xD;
             the Screening.&#xD;
&#xD;
          -  Participants who have undergone major surgery ≤ 2 months prior to start study drug.&#xD;
&#xD;
          -  Impaired cardiac function including clinically significant arrhythmias or clinically&#xD;
             significant abnormality in clinical test, including but not limited to any of the&#xD;
             following at Screening and&#xD;
&#xD;
        Check-in, repeat testing is allowed for verification, at the discretion of the&#xD;
        Investigator:&#xD;
&#xD;
          -  Heart rate &lt; 45 beats per minute (bpm) or &gt; 90 bpm (taken during blood pressure&#xD;
             measurement).&#xD;
&#xD;
          -  Systolic blood pressure (SBP) &lt; 90 mmHg or &gt; 140 mmHg; diastolic blood pressure (DBP)&#xD;
             &lt; 50 mmHg or &gt; 90 mmHg.&#xD;
&#xD;
          -  Average of the 3 QT intervals corrected using Fridericia's formula (QTcF) &gt; 450&#xD;
             milliseconds.&#xD;
&#xD;
          -  Second degree or higher Atrioventricular block on ECG&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) &lt; 90 ml/min/1.73m2&#xD;
&#xD;
               -  Impaired renal function or abnormal liver enzymes at baseline, including but not&#xD;
                  limited to:&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) &gt; upper limit of normal (ULN)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) &gt; ULN&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) &lt; 90 ml/min/1.73m2&#xD;
&#xD;
               -  Women who are pregnant or lactating, or intending to become pregnant before,&#xD;
                  during or within 90 days after exit from this study.&#xD;
&#xD;
               -  Women with baseline FSH ≥40mIU/ml&#xD;
&#xD;
               -  Participant who has had a loss of more than 100 mL blood (e.g., a blood donation)&#xD;
                  within 2 months before study drug administration, or has received any blood,&#xD;
                  plasma, or platelet transfusions within 3 months before Check-in, or plans to&#xD;
                  donate blood, ova or sperm during the study or within 3 months after the study.&#xD;
&#xD;
               -  Participant who has a known history of, or a positive test result for, hepatitis&#xD;
                  B surface antigen (HBsAg), hepatitis C virus (HCV), or human immunodeficiency&#xD;
                  virus (HIV) types 1 or 2 at screening.&#xD;
&#xD;
               -  Participant who has used prescription or over-the-counter (OTC) medication (other&#xD;
                  than ≤2 g/day paracetamol [acetaminophen] or ≤800 mg/day ibuprofen), vitamins, or&#xD;
                  herbal remedies, within 7 days or 5 half-lives before study drug administration,&#xD;
                  whichever is longer.&#xD;
&#xD;
               -  Participant who has a history of alcohol abuse (defined as an alcohol intake more&#xD;
                  than 21 units per week) or a history of drug abuse within the 6 months before&#xD;
                  study drug administration, or a history of substance abuse deemed significant by&#xD;
                  the investigator. A unit of alcohol is defined as 240 mL of beer, 120 mL of wine,&#xD;
                  or 20 mL of spirits.&#xD;
&#xD;
               -  Participant who smokes cigarettes or uses other nicotine-containing products&#xD;
                  (e.g., vape, snuff, nicotine patch, nicotine chewing gum, mock cigarettes, or&#xD;
                  inhalers), has done so in the 3 months prior to screening.&#xD;
&#xD;
               -  Consumption of caffeine or xanthine-containing food or beverages from at least 72&#xD;
                  hours prior to Check-in to the clinical research unit until at least 24 hours&#xD;
                  after last drug administration&#xD;
&#xD;
               -  Participant who has a positive test for alcohol or drugs of abuse (amphetamines,&#xD;
                  barbiturates, benzodiazepines, MDMA, oxycodone, phencyclidine, methamphetamine,&#xD;
                  tricyclic antidepressants, opiates, methadone, cocaine, cannabinoids,&#xD;
                  amphetamines, or cotinine) at Screening or Check-in.&#xD;
&#xD;
               -  Subject is unable to complete this study for other reasons or the Investigator&#xD;
                  believes that he or she should be excluded.&#xD;
&#xD;
               -  Participant who has a positive swab test of COVID-19 from Screening or Check-in&#xD;
                  testing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yolande Mucharbach</last_name>
    <phone>877-773-3707</phone>
    <email>Yolande.Mucharbach@ppd.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Las Vegas Clinical Research Unit</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yolande Mucharbach</last_name>
      <phone>877-773-3707</phone>
      <email>Yolande.Mucharbach@ppd.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>January 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2021</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

